Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology.
Ecke TH, Meisl CJ, Schlomm T, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T, Grunewald CM, Niegisch G, Hennig MJP, Kramer MW, Koch S, Roggisch J, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM, Klatte T. Ecke TH, et al. Among authors: niegisch g. Urology. 2024 Dec 1:S0090-4295(24)01113-0. doi: 10.1016/j.urology.2024.11.056. Online ahead of print. Urology. 2024. PMID: 39626834
A challenging discrimination of an intensely [18F]PSMA-1007-avid solitary lesion at the skull base in a patient with biochemical recurrence of prostate cancer.
Novruzov E, Niegisch G, Pauck D, Schmitt D, Kuhlmann J, Beseoglu K, Antoch G, Schimmöller L, Giesel FL, Mamlins E. Novruzov E, et al. Among authors: niegisch g. BJR Case Rep. 2024 Nov 1;10(6):uaae041. doi: 10.1093/bjrcr/uaae041. eCollection 2024 Nov. BJR Case Rep. 2024. PMID: 39553424 Free PMC article.
[Current developments in urothelial carcinoma].
Niegisch G, Kramer M. Niegisch G, et al. Urologie. 2024 Oct;63(10):975-976. doi: 10.1007/s00120-024-02442-z. Epub 2024 Oct 7. Urologie. 2024. PMID: 39373754 German. No abstract available.
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.
Hilser T, Darr C, Niegisch G, Schnabel MJ, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Niedersüß-Beke D, Grünwald V. Hilser T, et al. Among authors: niegisch g. Cancers (Basel). 2024 Aug 28;16(17):2998. doi: 10.3390/cancers16172998. Cancers (Basel). 2024. PMID: 39272856 Free PMC article.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
Grimm MO, Schostak M, Grün CB, Loidl W, Pichler M, Zimmermann U, Schmitz-Dräger B, Steiner T, Roghmann F, Niegisch G, Bolenz C, Schmitz M, Baretton G, Leucht K, Schumacher U, Foller S, Zengerling F, Meran J; TITAN-TCC Study Group. Grimm MO, et al. Among authors: niegisch g. JAMA Oncol. 2024 Jun 1;10(6):755-764. doi: 10.1001/jamaoncol.2024.0938. JAMA Oncol. 2024. PMID: 38722641 Clinical Trial.
168 results